Tag - CRDF

Markets

WB starts Cardiff Oncology at outperform

William Blair initiated coverage of Cardiff Oncology (NASDAQ:CRDF) with an “outperform” rating. The stock closed at $6.43 on Jan.4. Cardiff is advancing on vansertib, a specific PLK1 inhibitor, which “we view as a...

January 5, 2022

Markets

Maxim transfers coverage of Cardiff Oncology at buy; PT $20

Maxim Group transferred coverage of Cardiff Oncology (NASDAQ:CRDF) to analyst Naureen Quibria, Ph.D., with a “buy” rating and $20 price target. The stock closed at $5.76 on Aug. 6. Cardiff’s PLK inhibitor, onvansertib...

August 9, 2021

Developments

Cardiff Oncology onvansertib gets FDA fast track designation for colorectal cancer

Cardiff Oncology’s (NASDAQ:CRDF) onvansertib received FDA fast track designation for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The company is currently assessing...

May 28, 2020

Tag - CRDF

WB starts Cardiff Oncology at outperform

Maxim transfers coverage of Cardiff Oncology at buy; PT $20

Cardiff Oncology onvansertib gets FDA fast track designation for colorectal cancer

General

More